Bas Oldenburg

17.4k total citations · 2 hit papers
208 papers, 7.7k citations indexed

About

Bas Oldenburg is a scholar working on Genetics, Epidemiology and Surgery. According to data from OpenAlex, Bas Oldenburg has authored 208 papers receiving a total of 7.7k indexed citations (citations by other indexed papers that have themselves been cited), including 139 papers in Genetics, 101 papers in Epidemiology and 58 papers in Surgery. Recurrent topics in Bas Oldenburg's work include Inflammatory Bowel Disease (137 papers), Microscopic Colitis (89 papers) and Colorectal Cancer Screening and Detection (30 papers). Bas Oldenburg is often cited by papers focused on Inflammatory Bowel Disease (137 papers), Microscopic Colitis (89 papers) and Colorectal Cancer Screening and Detection (30 papers). Bas Oldenburg collaborates with scholars based in Netherlands, United States and Germany. Bas Oldenburg's co-authors include Peter D. Siersema, C. Janneke van der Woude, Maurice Lutgens, M.E.I. Schipper, G. P. van Berge Henegouwen, Itta M. Minderhoud, Saskia W. C. van Mil, Herma H. Fidder, Gerard Dijkstra and Karel J. van Erpecum and has published in prestigious journals such as Journal of Clinical Investigation, SHILAP Revista de lepidopterología and Gastroenterology.

In The Last Decade

Bas Oldenburg

200 papers receiving 7.6k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease

2011 656 citations Bas Oldenburg, M.E.I. Schipper et al. Gut profile →
Declining Risk of Colorectal Cancer in Inflammatory Bowel Disease

2013 371 citations Maurice Lutgens, Bas Oldenburg et al. Inflammatory Bowel Diseases profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Bas Oldenburg	4.2k	3.3k	2.5k	1.8k	999	208	7.7k
Daan W. Hommes	3.8k 0.9×	2.5k 0.8×	1.9k 0.8×	1.1k 0.6×	1.1k 1.1×	97	7.1k
Pieter Stokkers	4.0k 0.9×	2.5k 0.8×	2.2k 0.9×	1.0k 0.6×	768 0.8×	133	6.4k
Fernando Magro	5.5k 1.3×	4.2k 1.3×	2.4k 1.0×	786 0.4×	1.1k 1.1×	307	8.6k
Sandro Ardizzone	6.9k 1.6×	5.2k 1.6×	3.6k 1.4×	1.1k 0.6×	771 0.8×	236	10.7k
Livia Biancone	4.0k 0.9×	2.8k 0.9×	1.9k 0.7×	782 0.4×	1.1k 1.1×	199	6.9k
Gary R. Lichtenstein	5.7k 1.4×	4.6k 1.4×	2.3k 0.9×	772 0.4×	444 0.4×	237	8.6k
Bret A. Lashner	6.8k 1.6×	5.2k 1.6×	3.8k 1.5×	1.3k 0.7×	714 0.7×	191	10.1k
Morten H. Vatn	4.8k 1.1×	4.2k 1.2×	2.9k 1.2×	1.9k 1.1×	1.1k 1.1×	157	8.8k
Thomas Ullman	3.9k 0.9×	2.8k 0.8×	1.7k 0.7×	1.4k 0.7×	890 0.9×	129	6.3k
Miquel Sans	3.2k 0.8×	2.2k 0.7×	1.8k 0.7×	635 0.4×	1.1k 1.1×	109	6.0k

Countries citing papers authored by Bas Oldenburg

Since Specialization

Citations

This map shows the geographic impact of Bas Oldenburg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bas Oldenburg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bas Oldenburg more than expected).

Fields of papers citing papers by Bas Oldenburg

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bas Oldenburg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bas Oldenburg. The network helps show where Bas Oldenburg may publish in the future.

Co-authorship network of co-authors of Bas Oldenburg

This figure shows the co-authorship network connecting the top 25 collaborators of Bas Oldenburg. A scholar is included among the top collaborators of Bas Oldenburg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bas Oldenburg. Bas Oldenburg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Westerhout, Joost, et al.. (2025). Food Compounds Associated With Disease Activity in Inflammatory Bowel Disease. Inflammatory Bowel Diseases. 31(11). 3051–3059.

Meyer, Antoine, Franck Carbonnel, Christina C. Dahm, et al.. (2025). Fruits, Vegetables, Legumes, and Potatoes and Risk of Crohn's Disease and Ulcerative Colitis. The American Journal of Gastroenterology. 121(3). 733–744.

Broeder, Nathan den, Debora de Jong, Marjolijn Duijvestein, et al.. (2024). OP15 High-definition white light endoscopy with segmental re-inspection is non-inferior compared to dye-based chromoendoscopy in Inflammatory Bowel Disease: the randomized controlled HELIOS trial. Journal of Crohn s and Colitis. 18(Supplement_1). i29–i30. 4 indexed citations

Elias, Sjoerd G., Evelien Dekker, Herma H. Fidder, et al.. (2023). Smoking and colorectal neoplasia in patients with inflammatory bowel disease: Dose‐effect relationship. United European Gastroenterology Journal. 11(7). 612–620. 3 indexed citations

Verheijden, Rik J., Stefan Nierkens, Anne S. R. van Lindert, et al.. (2023). Toxicity-specific peripheral blood T and B cell dynamics in anti-PD-1 and combined immune checkpoint inhibition. Cancer Immunology Immunotherapy. 72(12). 4049–4064. 15 indexed citations

Albéniz, Eduardo, James E. East, Nayantara Coelho‐Prabhu, et al.. (2022). Endoscopic management of patients with high-risk colorectal colitis–associated neoplasia: a Delphi study. Gastrointestinal Endoscopy. 97(4). 767–779.e6. 10 indexed citations

Muntjewerff, Elke M., Kechun Tang, Gustaf Christoffersson, et al.. (2021). Chromogranin A regulates gut permeability via the antagonistic actions of its proteolytic peptides. Acta Physiologica. 232(2). e13655–e13655. 19 indexed citations

Brand, Eelco C., Sjoerd G. Elias, Itta M. Minderhoud, et al.. (2019). Systematic Review and External Validation of Prediction Models Based on Symptoms and Biomarkers for Identifying Endoscopic Activity in Crohn's Disease. Clinical Gastroenterology and Hepatology. 18(8). 1704–1718. 19 indexed citations

Dreesen, Erwin, Filip Baert, David Laharie, et al.. (2019). Monitoring a Combination of Calprotectin and Infliximab Identifies Patients With Mucosal Healing of Crohn’s Disease. Clinical Gastroenterology and Hepatology. 18(3). 637–646.e11. 60 indexed citations

10.

Simsek, Melek, Birgit I. Lissenberg‐Witte, Frank Hoentjen, et al.. (2019). Off‐label prescriptions of drugs used for the treatment of Crohn’s disease or ulcerative colitis. Alimentary Pharmacology & Therapeutics. 49(10). 1293–1300. 3 indexed citations

11.

Shah, Shailja C., Joana Torres, Daniel Castañeda, et al.. (2019). Association Between Indefinite Dysplasia and Advanced Neoplasia in Patients With Inflammatory Bowel Diseases Undergoing Surveillance. Clinical Gastroenterology and Hepatology. 18(7). 1518–1527.e3. 24 indexed citations

12.

Shah, Shailja C., Joren R. ten Hove, Daniel Castañeda, et al.. (2018). High Risk of Advanced Colorectal Neoplasia in Patients With Primary Sclerosing Cholangitis Associated With Inflammatory Bowel Disease. Clinical Gastroenterology and Hepatology. 16(7). 1106–1113.e3. 73 indexed citations

13.

Shah, Shailja C., Joren R. ten Hove, Joana Torres, et al.. (2018). No Association Between Pseudopolyps and Colorectal Neoplasia in Patients With Inflammatory Bowel Diseases. Gastroenterology. 156(5). 1333–1344.e3. 54 indexed citations

14.

Bodegraven, Adriaan A. van, Nathalie Bravenboer, Birgit I. Lissenberg‐Witte, et al.. (2013). Treatment of bone loss in osteopenic patients with Crohn's disease: a double-blind, randomised trial of oral risedronate 35 mg once weekly or placebo, concomitant with calcium and vitamin D supplementation. Gut. 63(9). 1424–1430. 18 indexed citations

15.

Manderson, Lenore, Rachel Canaway, Bas Oldenburg, et al.. (2012). Care seeking, use of complementary therapies and self management among people with type 2 diabetes and cardiovascular disease. Victoria University Research Repository (Victoria University). 2 indexed citations

16.

Connolly, Mark P., Cornelis Boersma, & Bas Oldenburg. (2012). The economics of mesalazine in active ulcerative colitis and maintenance in the Netherlands.. PubMed. 70(6). 272–7. 6 indexed citations

17.

Vos, Anne Christine W., Robert C. Minnee, Dirk J. de Jong, et al.. (2010). Risk of malignant lymphoma in patients with inflammatory bowel diseases: A Dutch nationwide study. Inflammatory Bowel Diseases. 17(9). 1837–1845. 74 indexed citations

18.

Schwartz, Matthijs P., et al.. (2008). C-reactive protein levels during a relapse of Crohn’s disease are associated with the clinical course of the disease. World Journal of Gastroenterology. 14(1). 85–85. 37 indexed citations

19.

Vleggaar, F.P., Maurice Lutgens, Bas Oldenburg, M.E.I. Schipper, & Melvin Samsom. (2007). [British and American screening guidelines inadequate for prevention of colorectal carcinoma in patients with inflammatory bowel disease].. PubMed. 151(50). 2787–91. 5 indexed citations

20.

Schrijvers, A.J.P., et al.. (2006). Infliximab use in patients with Crohn's disease: quality of life, costs and resource use.. PubMed. 64(7). 212–8. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact